PDF(Pubmed)
Abstract：
Systemically administered immunotherapies have revolutionized the care of patients with cancer; however, for many cancer types, most patients do not exhibit objective responses. Intratumoral immunotherapy is a burgeoning strategy that is designed to boost the effectiveness of cancer immunotherapies across the spectrum of malignancies. By locally administering immune-activating therapies into the tumor itself, immunosuppressive barriers in the tumor microenvironment can be broken. Moreover, therapies too potent for systemic delivery can be safely administered to target location to maximize efficacy and minimize toxicity. In order for these therapies to be effective, though, they must be effectively delivered into the target tumor lesion. In this review, we summarize the current landscape of intratumoral immunotherapies and highlight key concepts that influence intratumoral delivery, and by extension, efficacy. We also provide an overview of the breadth and depth of approved minimally invasive delivery devices that can be considered to improve delivery of intratumoral therapies.
摘要：
系统管理的免疫疗法彻底改变了癌症患者的护理;然而，对于许多癌症类型，大多数患者没有表现出客观的反应。肿瘤内免疫治疗是一种新兴的策略，旨在提高整个恶性肿瘤范围内癌症免疫疗法的有效性。通过对肿瘤本身进行局部免疫激活疗法，肿瘤微环境中的免疫抑制屏障可以被打破。此外，对于全身给药过于有效的疗法可以安全地施用到目标位置,以最大化疗效和最小化毒性.为了使这些疗法有效，虽然,它们必须被有效地递送到靶肿瘤病灶中。在这次审查中,我们总结了肿瘤内免疫疗法的现状，并强调了影响肿瘤内递送的关键概念，引申开来,功效。我们还提供了已批准的微创递送装置的广度和深度的概述，这些装置可以被认为可以改善肿瘤内治疗的递送。
